MCL: Clinical Trials

2 trials for MCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Terminated 2

Follow MCL: new trials by email Literature Review of MCL trials Research Report on MCL

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Tafasitamab, Lenalidomide - Mantle Cell Lymphoma, MCL
Phase 2TerminatedMemorial Sloan Kettering Cancer Center42023-03-142025-05-25
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
90Y-DOTATOC - DLBCL, MCL
Phase 2TerminatedIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS12016-12-222018-03-19

Narrower conditions

Lymphoma, Mantle-Cell (2)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

90Y-octreotide, DOTA-Tyr(3)- (1)  ·  Lenalidomide (1)  ·  tafasitamab (1)

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

Italy (1)  ·  United States (1)

Top investigators

Anita Kumar, MD (1)  ·  Maddalena Sansovini, MD (1)